Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    1(33%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Early Phase 1
    1
    33%
    Phase 1
    1
    33%
    Phase 2
    1
    33%

    Phase Distribution

    2

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Early Phase 1First-in-human
    1(33.3%)
    Phase 1Safety & dosage
    1(33.3%)
    Phase 2Efficacy & side effects
    1(33.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    2 of 2 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(1)
    Completed(2)

    Detailed Status

    Completed2
    Active, not recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Early Phase 11 (33.3%)
    Phase 11 (33.3%)
    Phase 21 (33.3%)

    Trials by Status

    completed267%
    active_not_recruiting133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    active_not_recruitingphase_2

    Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

    NCT06799234
    completedearly_phase_1

    Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

    NCT04754776
    completedphase_1

    A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

    NCT04672824

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT06799234Phase 2

    Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

    Active Not Recruiting
    NCT04754776Early Phase 1

    Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

    Completed
    NCT04672824Phase 1

    A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    3